Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer

70Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Increased expression of urokinase plasminogen activator (uPA) has been reported in various malignancies including prostate cancer. However, the mechanism by which uPA is abnormally expressed in prostate cancer remains elusive. Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples. This aberrant expression is associated with cancer-linked demethylation of the uPA promoter. Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo. Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors. ©2007 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Pulukuri, S. M. K., Estes, N., Patel, J., & Rao, J. S. (2007, February 1). Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/0008-5472.CAN-06-2892

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free